Clonal haematopoiesis and dysregulation of the immune system

R Belizaire, WJ Wong, ML Robinette… - Nature Reviews …, 2023‏ - nature.com
Age-related diseases are frequently linked to pathological immune dysfunction, including
excessive inflammation, autoreactivity and immunodeficiency. Recent analyses of human …

SOCS proteins in immunity, inflammatory diseases, and immune-related cancer

ML Sobah, C Liongue, AC Ward - Frontiers in medicine, 2021‏ - frontiersin.org
Cytokine signaling represents one of the cornerstones of the immune system, mediating the
complex responses required to facilitate appropriate immune cell development and function …

The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee

E Campo, ES Jaffe, JR Cook… - Blood, The Journal …, 2022‏ - ashpublications.org
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …

Combination targeted therapy in relapsed diffuse large B-cell lymphoma

C Melani, R Lakhotia, S Pittaluga… - … England Journal of …, 2024‏ - Mass Medical Soc
Background The identification of oncogenic mutations in diffuse large B-cell lymphoma
(DLBCL) has led to the development of drugs that target essential survival pathways, but …

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

WH Wilson, GW Wright, B Hodkinson… - Cancer cell, 2021‏ - cell.com
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …

Genomic profiling for clinical decision making in lymphoid neoplasms

L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022‏ - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma

E Bal, R Kumar, M Hadigol, AB Holmes, LK Hilton… - Nature, 2022‏ - nature.com
Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma
and remains incurable in around 40% of patients. Efforts to sequence the coding genome …

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population

W Alduaij, B Collinge, S Ben-Neriah… - Blood, The Journal …, 2023‏ - ashpublications.org
Molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) underlies the variable
outcomes achieved with immunochemotherapy. However, outcomes of gene expression …

The genomic and transcriptional landscape of primary central nervous system lymphoma

J Radke, N Ishaque, R Koll, Z Gu, E Schumann… - Nature …, 2022‏ - nature.com
Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell
lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of …

RNA-based diagnostic markers discovery and therapeutic targets development in cancer

H Wang, Q Meng, J Qian, M Li, C Gu, Y Yang - Pharmacology & …, 2022‏ - Elsevier
The present review aimed to outline different types of RNAs in cancer diagnostics and
treatment, and to provide novel insights into their clinical applications. RNAs, including …